Passage Bio, Inc. Company Analysis & Research
Passage Bio is a clinical-stage genetic medicines company focused on developing one-time therapies targeting the underlying pathology of neurodegenerative diseases. The lead product candidate, PBFT02, seeks to treat frontotemporal dementia by elevating progranulin levels to restore lysosomal function and slow disease progression.
Passage Bio delivered promising data in 2024 showing durable progranulin expression and completed development and scale-up of a high-productivity, suspension-based manufacturing process. The company benefits from strategic research collaboration with the Trustees of the University of Pennsylvania's Gene Therapy Program and partnership agreements with Catalent Maryland.
Company Overview
Founded: 2017. Headquarters: Philadelphia, US. Revenue: $35M. Employees: 65. Ticker: PASG (NASDAQ).
Industry
Genetic Medicines / Gene Therapy - CNS Neurodegenerative Diseases
Cyborg Score: 7/10 — Strong
Clinical validation of PBFT02 with extended cash runway and FDA alignment positions Passage Bio for pivotal trial progression in high-value neurodegenerative disease market.
Passage Bio reported significant positive updates on PBFT02 clinical trial with promising interim results including robust progranulin elevation and improvement in disease progression biomarkers. Cash runway extends into Q1 2027 with $52.8M in cash and equivalents as of September 2025. Strong analyst support with recent analyst initiations and upgrades, consensus "Strong Buy" rating with $34.50 average price target as of February 2026.
Key Strategic Insights for Passage Bio, Inc.
- Dose 2 PBFT02 is 50% lower than Dose 1, with expectations to report 12-month data from Dose 1 and interim safety data from Dose 2 in H2 2025
- Actively enrolling patients in Cohorts 3-4 of upliFT-D study targeting FTD-GRN and FTD-C9orf72 variants with protocol amendments for broader early-stage enrollment
- FDA-aligned manufacturing process produced batch yielding >1,000 doses at >90% purity and >70% full capsids, demonstrating scalability
- Completed 1-for-20 reverse stock split in July 2025, reducing shares from 62.4M to 3.1M to maintain Nasdaq compliance
Recent Developments
- (November 2025) Reported positive interim data from upliFT-D study Cohort 2 with robust progranulin elevation and biomarker improvement
- (November 2025) Announced FDA alignment on analytical comparability for suspension-based PBFT02 manufacturing process
- (July 2025) Completed 1-for-20 reverse stock split to regain Nasdaq minimum bid price compliance
- (March 2025) Extended cash runway into Q1 2027 following 2024 financial results announcement
Competitors & Competitive Landscape
- Sarepta Therapeutics — Focused on genetic medicines for rare neurological conditions
- CRISPR Therapeutics — Develops gene therapies for severe rare conditions
- Intellia Therapeutics — Develops gene therapies for severe rare neurological conditions
Passage Bio competes in AAV gene therapy space with competitors including Sarepta Therapeutics focused on rare neurological diseases and CRISPR/Intellia Therapeutics developing gene therapies for severe rare neurological conditions. Passage Bio differentiates through focused CNS neurodegenerative disease portfolio and proprietary suspension-based manufacturing approach enabling potential dose flexibility.
More Company Research
CS Diagnostics Corp. Keyrus S.A. Squirrel Media, S.A. Schweiter Technologies AG Abraj Energy Services SAOG East Pipes Integrated Company for Industry Neuren Pharmaceuticals Limited MVV Energie AG Hangzhou EZVIZ Network Co., Ltd. PT Sumber Alfaria Trijaya Tbk Globalstar, Inc. Computershare Limited Hubbell Incorporated ITOCHU Corporation SaverOne 2014 Ltd.Full Company Research Reports
Looking for a more in-depth analysis of Passage Bio, Inc.? AskCyborg's Company Research section contains full AI-generated reports with detailed financials, strategic analysis, and Cyborg Score ratings. Browse the complete company research library or explore industry research reports.
AskCyborg provides AI-powered company research and analysis. Visit AskCyborg for full reports, Cyborg Score ratings, and analyst podcasts.